Pegylated Liposomal Irinotecan

A formulation of polyethylene glycol (PEG)-modified liposomes encapsulating the semisynthetic derivative of camptothecin irinotecan, with… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2009-2018
0120092018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
The National Institute for Health and Care Excellence (NICE) invited the manufacturer (Shire Pharmaceuticals) of pegylated… (More)
Is this relevant?
2015
2015
IHL-305 is a PEGylated liposomal formulation of irinotecan (CPT-11). The objective of this study was to evaluate the factors… (More)
  • table 1
  • figure 2
  • figure 1
  • figure 3
  • table 2
Is this relevant?
2012
2012
IHL-305 is a novel PEGylated liposome containing irinotecan. This study examined the safety profile and pharmacokinetics of IHL… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
Is this relevant?
2012
2012
Medullary thyroid carcinoma is a rare endocrine tumor, which shows overexpression of somatostatin receptor subtype 2. There is no… (More)
Is this relevant?
2011
2011
OBJECTIVES Liposomal delivery of irinotecan could provide protection against drug hydrolysis, deliver more active lactone form to… (More)
Is this relevant?
2009
2009
2547 Background: Irinotecan (CPT-11) is a prodrug of SN-38 that has antitumor activity in a wide range of solid tumors. IHL- 305… (More)
Is this relevant?